About SGMO
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm... [Read more]
Industry Biotechnology
Sector Healthcare
IPO Date Apr 6, 2000
Employees 405
Stock Exchange NASDAQ
Ticker Symbol SGMO
Full Company Profile
Financial Performance
In 2023, SGMO's revenue was $176.23 million, an increase of 58.34% compared to the previous year's $111.30 million. Losses were -$257.83 million, 34.1% more than in 2022.
Financial Statements
Analyst Forecast
According to 7 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $5.17, which is an increase of 773.75% from the latest price.
Price Target
$5.17
(773.75% upside)
Analyst Consensus: Buy
Stock Forecasts
News
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS.
4 weeks ago - Business Wire
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing.
4 weeks ago - Business Wire
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast.
5 weeks ago - Business Wire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT.
6 weeks ago - Business Wire
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES PRICING OF $24.0 MILLION REGISTERED DIRECT OFFERING.
2 months ago - Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results.
3 months ago - Business Wire
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES DATA FROM PROPRIETARY NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING BLOOD-BRAIN BARRIER PENETRATION & BRAIN TRANSDUCTION.
3 months ago - Business Wire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
3 months ago - Business Wire
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA ALIGNMENT ON ABBREVIATED PATHWAY TO POTENTIAL APPROVAL AND EMA PRIME ELIGIBILITY FOR ST-920 IN FABRY DISEASE.
4 months ago - Business Wire
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY DISEASE SHOWING SUSTAINED BENEFIT AND DIFFERENTIATED SAFETY PROFILE.
4 months ago - Business Wire
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS.
7 months ago - Business Wire
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast.
8 months ago - Business Wire
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT.
8 months ago - Business Wire
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit.
9 months ago - Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS.
10 months ago - Business Wire
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES SECOND QUARTER 2023 CONFERENCE CALL AND WEBCAST.
11 months ago - Business Wire
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
BRISBANE, Calif. & BOSTON--(BUSINESS WIRE)--SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION AND LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS FOR EPIGENETIC EDITING.
11 months ago - Business Wire
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Thera...
11 months ago - Business Wire
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
BRISBANE, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties ...
Other symbols: VYGR
1 year ago - Business Wire
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ISARALGAGENE CIVAPARVOVEC FOR THE TREATMENT OF FABRY DISEASE.
1 year ago - Business Wire
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF LISA ROJKJAER, M.D., AS CHIEF MEDICAL OFFICER.
1 year ago - Business Wire
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Other symbols: ACCDBIODGXSHC
1 year ago - Benzinga
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT PRE-CLINICAL DATA FROM ITS GENOMIC ENGINEERING PLATFORM AT ASGCT.
1 year ago - Business Wire
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS.
1 year ago - Business Wire
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial resu...
1 year ago - Business Wire